Vascular Lipolysis: A Determinant of Atherosclerosis
血管脂肪分解:动脉粥样硬化的决定因素
基本信息
- 批准号:6369438
- 负责人:
- 金额:$ 38.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-01 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:atherosclerosis carboxylic ester hydrolases ceramides dietary lipid gene expression genetic polymorphism genetic screening genetic strain genetic susceptibility genetically modified animals isozymes laboratory mouse lipase lipid metabolism lipolysis low density lipoprotein low density lipoprotein receptor lysolecithins molecular pathology nutrition related tag oxidized lipid pathogenic diet site directed mutagenesis vascular endothelium
项目摘要
DESCRIPTION (provided by applicant): Recent studies have clearly documented the importance of phospholipid and sphingolipid metabolites in atherosclerosis and
vascular biology. While enzymes responsible for phospholipid and sphingomyelin
hydrolysis in the vessel wall have been identified and were shown to contribute
to atherogenesis, enzyme(s) responsible for lowering the level of their
hydrolytic products, the bioactive lysophosphatidylcholine (LysoPC) and
ceramide, have not been characterized to date. Results generated from this
laboratory revealed the presence of the pancreatic-type carboxyl ester lipase
(CEL) in human vascular wall. This protein is synthesized by aortic endothelial
cells and monocyte-derived macrophages in a manner inducible by oxidized LDL
(oxLDL). Importantly, CEL displayed avid bile salt-independent lysoPC and
ceramide hydrolytic activities. Human CEL is also highly polymorphic, encoding
proteins varying in the number of proline-rich repeating units at the carboxyl
terminus. Based on these novel observations, this application proposes to test
the following hypotheses: (1) CEL expression in the vasculature is an
inflammatory response mechanism that protects early stages of atherogenesis by
hydrolyzing and reducing the atherogenic properties of lysoPC and ceramide; (2)
the number of proline-rich repeating units in the C-terminus of CEL is
important in determining its ability to hydrolyze lysoPC and ceramide; and (3)
CEL gene polymorphism is a determinant of individual susceptibility to
modified-LDL mediated atherogenic events. These hypotheses viii be tested by
experiments under 3 specific aims. Specific Aim 1 plans to produce
vascular-specific CEL transgenic mice to evaluate the impact of vascular CEL
gene expression on initiation and progression of the atherosclerotic plaque.
Specific Aim 2 will use site-directed mutagenesis approach to test the
hypothesis that the number of proline-rich repeating units at its C-terminus is
an important determinant of lysoPC and ceramide hydrolytic activities of CEL,
and thus the effectiveness of different CEL isoforms in protecting vascular
cells against lysoPC- and ceramide-induced atherogenic events. Specific Aim 3
will identify the mechanism by which modified LDL induces CEL gene expression
in human macrophages and endothelia cells. Experiments will be designed to test
the hypothesis that CEL gene activation is mediated via signal transduction
mechanisms as a consequence of oxLDL binding to scavenger receptors on the cell
surface, or alternatively requires the internalization of specific lipid
constituents associated with oxidized lipoproteins. Taken together, these
studies will identify novel factors that contribute to determining
atherosclerosis susceptibility. Genetic screening strategy may also be designed
to identify subjects predispose to atherosclerosis for early intervention and
reducing their risk of developing this disease.
描述(由申请人提供):最近的研究已经清楚地证明了磷脂和鞘脂代谢物在动脉粥样硬化和动脉粥样硬化中的重要性
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Yiu-Kwan Hui其他文献
David Yiu-Kwan Hui的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Yiu-Kwan Hui', 18)}}的其他基金
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
多态性 ApoE 处于动脉粥样硬化脂质代谢和炎症十字路口
- 批准号:
10533337 - 财政年份:2021
- 资助金额:
$ 38.25万 - 项目类别:
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
多态性 ApoE 处于动脉粥样硬化脂质代谢和炎症十字路口
- 批准号:
10363587 - 财政年份:2021
- 资助金额:
$ 38.25万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10167112 - 财政年份:2020
- 资助金额:
$ 38.25万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10582114 - 财政年份:2019
- 资助金额:
$ 38.25万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
9761773 - 财政年份:2019
- 资助金额:
$ 38.25万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10375435 - 财政年份:2019
- 资助金额:
$ 38.25万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
9889159 - 财政年份:2019
- 资助金额:
$ 38.25万 - 项目类别:
Intestinal LPC/LPA modulation of gut microbiota and metabolic disease
肠道 LPC/LPA 对肠道微生物群和代谢疾病的调节
- 批准号:
9354489 - 财政年份:2016
- 资助金额:
$ 38.25万 - 项目类别:
Role of Endothelial and Macrophage ApoER2 in Atherosclerosis Modulation
内皮细胞和巨噬细胞 ApoER2 在动脉粥样硬化调节中的作用
- 批准号:
9211369 - 财政年份:2014
- 资助金额:
$ 38.25万 - 项目类别:
Role of Endothelial and Macrophage ApoER2 in Atherosclerosis Modulation
内皮细胞和巨噬细胞 ApoER2 在动脉粥样硬化调节中的作用
- 批准号:
8794465 - 财政年份:2014
- 资助金额:
$ 38.25万 - 项目类别: